Form 4: MannKind Director Steven Binder Executes Stock Sale

Director Steven B. Binder reported the sale of 16,940 shares of MannKind Corporation common stock following a tax-related share withholding.

Summary

• Director Steven B. Binder disposed of 5,560 shares on May 11, 2026, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
• Director Steven B. Binder sold 16,940 shares on May 12, 2026, at a weighted average price of $3.29 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan established on December 2, 2025.
• Following these transactions, the reporting person maintains beneficial ownership of 808,008 shares of MannKind common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-planned 10b5-1 arrangement and represent routine portfolio management.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to divestment rather than reactive selling.

Negatives

• The filing reflects a reduction in the direct equity stake held by a member of the Board of Directors.

Risks

• None identified in this specific Form 4 filing.

Future Outlook

No forward-looking guidance provided in this document.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice, typically used by executives and directors to provide liquidity while avoiding concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings in compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected as the sale was conducted via a pre-planned trading program.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

MannKind, MNKD, Insider Trading, Form 4, Director Sale, Biotech